2226-86-0

Basic information

• Product Name: ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE
• Synonyms: ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE;2,4-DiMethyl-pyriMidine-5-carboxylic acid ethyl ester;NSC 165510
• CAS NO: 2226-86-0
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.2
• Mol File: 2226-86-0.mol

Chemical Properties

• Boiling Point: 252℃
• Flash Point: 107℃
• Appearance: /
• Density: 1.106
• Vapor Pressure: 0.0192mmHg at 25°C
• Refractive Index: 1.4942
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE(2226-86-0)
• EPA Substance Registry System: ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE(2226-86-0)

Safety Data

• Hazardous Substances Data: 2226-86-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE is used as a building block in organic synthesis for its versatile reactivity and structural properties, allowing for the creation of a variety of complex organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE is used as a key intermediate in the development of new drugs, owing to its potential to be incorporated into medicinal compounds with desired therapeutic effects.
Used in Agrochemical Development:
ETHYL-2,4-DIMETHYL-5-PYRIMIDINE CARBOXYLATE is also utilized in the field of agrochemicals, serving as a component in the synthesis of new pesticides or other agricultural chemicals, highlighting its broad applicability in chemical innovation.

InChI:InChI=1/C9H12N2O2/c1-4-13-9(12)8-5-10-7(3)11-6(8)2/h5H,4H2,1-3H3

Upstream product

• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 143-37-3 acetamidine 
• 49836-24-0 (E)-2-(ethoxymethylene)-3-oxobutanoic acid ethyl ester 
• 141-97-9 ethyl acetoacetate 
• 124-42-5 acetamidine hydrochloride 
• 134653-70-6 α-acetyl-α-(dimethylaminomethylene)acetic acid,ethyl ester 
• 3788-94-1 2-ethoxymethylene-3-oxobutanoic acid ethyl ester 
• 66975-53-9 2-1-ethoxy-meth-(Z)-ylidene-3-oxo-butyric acid ethyl ester 

Downstream Products

• 108718-87-2 N-acetyl-sulfanilic acid-(2,4-dimethyl-pyrimidin-5-ylamide) 
• 7411-79-2 2,4-dimethyl-4-amino-N-5-pyrimidinylbenzenesulfonamide 
• 35733-53-0 5-amino-2,4-dimethylpyrimidine 
• 14331-54-5 2,4-dimethylpyrimidine 
• 74840-42-9 (2,4-dimethyl-5-pyrimidinyl)diphenyl-(1-imidazolyl)methane 
• 88317-45-7 2,4-dimethylpyrimidine-5-carbohydrazide 
• 74356-36-8 2,4-dimethylpyrimidine-5-carboxylic acid 
• 74840-41-8 α-(2,4-dimethyl-5-pyrimidinyl)benzhydrol 
• 53554-30-6 2,4-Dimethyl-pyrimidin-5-carbonsaeure-amid 

Relevant articles and documents

Pyrido/pyridazocyclic compound and application thereof

The invention discloses a pyrido/pyridazocyclic compound, a pharmaceutically acceptable salt and a solvent compound thereof. The invention further provides a preparation method of the compound, a composition with the compound and application of the compound for preparing medicines for treating diseases or disorders related to EED (embryonic ectoderm development) protein and/or PRC2 (polycomb repressive complex 2) protein composition action mechanisms.

PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

Dpp-IV inhibitors

The invention relates to compounds of formula (I) wherein R1, R2, R3 and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the prep

MEDICINAL COMPOSITIONS

The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

JNK INHIBITOR

The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

Reaction of 2-Dimethylaminomethylene-1,3-diones with Dinucleophiles. VIII. Synthesis of Ethyl and Methyl 2,4-Disubstituted 5-Pyrimidinecarboxylates

Reaction of ethyl or methyl 2-dimethylaminomethylene-3-oxoalkanoates with N-C-N dinucleophiles such as guanidine, acetamidine or benzamidine afforded in high yields the relative esters of 4-substituted 2-amino-, 2-methyl- or 2-phenyl-5-pyrimidinecarboxylic acids, respectively.These esters were hydrolyzed to the corresponding carboxylic acids, which were converted by heating to 4-substituted 2-pyrimidinamines, 2-methyl or 2-phenylpyrimidines, respectively, generally in excellent yields.The 4-unsubstituted ethyl 2-amino-, 2-methyl- and 2-phenyl-5-pyrimidinecarboxylateswere obtained in moderate yields by reaction of the above dinucleophiles with ethyl 2,2-diformylacetate.These esters were hydrolyzed and the corresponding acids (with the exception of the 2-methyl derivative) were decarboxylated to give 2-pyrimidinamine and 2-phenylpyrimidine in satisfactory yields.